300,227 Shares in Haleon plc (NYSE:HLN) Bought by William Blair Investment Management LLC

William Blair Investment Management LLC purchased a new position in shares of Haleon plc (NYSE:HLN) in the 1st quarter, HoldingsChannel reports. The institutional investor purchased 300,227 shares of the company’s stock, valued at approximately $2,549,000.

Several other hedge funds have also recently modified their holdings of HLN. Hexagon Capital Partners LLC raised its position in Haleon by 107.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock worth $35,000 after acquiring an additional 2,193 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Haleon by 853.4% in the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock worth $39,000 after acquiring an additional 4,267 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Haleon in the first quarter worth $43,000. Tower Research Capital LLC TRC raised its position in Haleon by 146.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock worth $44,000 after acquiring an additional 3,211 shares in the last quarter. Finally, SRS Capital Advisors Inc. raised its position in Haleon by 456.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock worth $45,000 after acquiring an additional 4,477 shares in the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

Haleon stock traded up $0.17 during midday trading on Wednesday, reaching $8.92. 3,681,820 shares of the company were exchanged, compared to its average volume of 5,246,460. The company has a market capitalization of $40.73 billion, a price-to-earnings ratio of 29.73, a P/E/G ratio of 2.52 and a beta of 0.24. The firm’s 50-day simple moving average is $8.48 and its 200-day simple moving average is $8.38. Haleon plc has a 1 year low of $7.70 and a 1 year high of $8.96. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Haleon had a return on equity of 13.17% and a net margin of 9.68%. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. On average, analysts anticipate that Haleon plc will post 0.46 EPS for the current year.

Analysts Set New Price Targets

HLN has been the subject of several research analyst reports. HSBC initiated coverage on Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating for the company. Argus restated a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Finally, Berenberg Bank began coverage on Haleon in a research report on Wednesday, June 5th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Haleon currently has an average rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.